Trimethoprim-sulfamethoxazole Graded Administration in Oncology, Hematopoietic Stem Cell Transplant, and Solid Organ Transplant Patients with a History of Sulfonamide Allergy


About this study

The aim of this study is to study the efficacy and safety of our short and long one-day protocols for TMP-SMX graded administration in hematologic malignancy, hematopoietic stem cell transplant, and solid organ transplant patients.    

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. History of sulfonamide allergy
  2. Diagnosis of hematologic malignancy OR solid organ or hematopoietic stem cell transplant recipient
  3. Requires PCP prophylaxis

Exclusion Criteria: 

  1. History of a severe reaction to TMP-SMX including Stevens Johnson syndrome, toxic epidermal necrolysis, anaphylaxis, drug reaction with eosinophilia and systemic symptoms, serum sickness, vasculitis, severe mucosal ulcerations, cytopenias or other severe reactions with significant systemic involvement.  

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Miguel Park, M.D.

Contact us for the latest status

Contact information:

Miguel Park M.D.


More information


Publications are currently not available

Mayo Clinic Footer